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1. Introduction
   Ebola virus is a filovirus that can cause fatal infection in human 
beings. Ebola virus outbreak in Africa in 2014 is a big global 
issue. Thousands of local Africans get infections and the disease 
has already spread out of Africa. The vaccine is the hope for 
management of the present outbreak of Ebola virus infection[1,2]. 
There are several ongoing researches on new Ebola virus vaccine. 
The trials for many newly developed vaccine candidates are 
planned[3]. In this short manuscript, we discuss and put forward 
specific remained problems to be answered on this specific issue.
2. Points to be discussed
   As a new emerging infectious disease, the development of Ebola 
virus vaccine is a challenge. Finding for pandemic vaccine has to be 
rapidly done and this is usually questionable for the effectiveness 
and safety, similar to the situation of the previous 2009 swine flu 
outbreak[4]. 
   First, the basic search for immunological epitope and further 
peptide candidate development can be done with the help of 
advanced bioinformatics and biotechnology in the present. The in 
silico computational process can be helpful. There are many newly 
developed vaccine candidates and ongoing researches on Ebola 
vaccine development. The great consideration is on the knowledge 
of the virus and its immunological biological system. It is not fully 
known and further basic medical science research is still needed[5]. 
Interestingly, most vaccine researches on the present Ebola virus 
outbreak use the accumulated data from previous small outbreaks. 
The present 2014 African Ebola virus outbreak has some new 
clinical features which might relate to the difference in basic 
genetic composition of the virus[6]. The realization on the new 
virus and its immunological aspects is very important and this is 
the first step for success in vaccine search and development. Hence, 
the vaccine candidates that were developed based on old viral data 
are questionable for the effectiveness.
   Second, since the present outbreak occurs at a poor region of the 
world, West Africa, the limitation of local facilities corresponding 
to medical research can be expected. In addition, the interest on 
vaccine development by the main pharmaceutical company of the 
world might not be much at the early phase of outbreak. For sure, 
many tropical infectious diseases in poor tropical countries usually 
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get less interest on funding and research for vaccine development 
by pharmaceutical company[7]. Indeed, Ebola virus has been 
detected for many decades but it seems to be a neglected tropical 
disease[8]. As noted by Geisbert and Jahrling, small global market 
has generated little commercial interest for developing an Ebola 
virus vaccine[9]. There are very few medical developments on this 
infection before there is a present concern on its possible worldwide 
pandemic. Call for urgent international collaboration to find new 
drug and vaccine is the present need[10]. Funding for more research 
and development in new drug discovery and vaccines is the urgent 
requirement as suggested by Tambo et al[11].
   Third, for the already newly developed vaccine candidates, the 
remained problem is the vaccine trial. Since the required vaccine 
is the pandemic vaccine, the complete process of vaccine trial 
is impossible. Although there have been some previous reports 
on Ebola vaccine trials in animal model, those vaccines cannot 
correspond to the present new emerging problems[12,13]. The 
clinical trial in human beings without data in animal test becomes a 
widely discussed ethical issue[14,15]. Focusing on the present human 
trial, most trials are only in phase I and it is still a long way to get 
the completely guaranteed vaccines[16]. The availability of the new 
vaccine might be late to correspond the present rapidly spreading 
of the infection. Hence, there is no doubt that the national health 
policies of many countries promote the urgent trail of the new 
vaccine[17,18].
3. Conclusion
   Conclusively, the Ebola virus vaccine is the hope for management 
of the present outbreak of Ebola virus infection in Africa. However, 
the effective vaccine is still no available. There are several 
remained problems for the vaccine development. Lack for complete 
knowledge on the new emerging virus, lack for concern from 
pharmaceutical company and lack for good trial of new vaccine 
candidates are the remained problems to be further discussed in 
vaccinology.  
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